- Home
- PALI vs CPHI Comparison
PALI vs CPHI Comparison
Compare PALI & CPHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PALI
- CPHI
- Stock Information
- Founded
- PALI 1996
- CPHI N/A
- Country
- PALI United States
- CPHI China
- Employees
- PALI N/A
- CPHI N/A
- Industry
- PALI Biotechnology: Biological Products (No Diagnostic Substances)
- CPHI Biotechnology: Pharmaceutical Preparations
- Sector
- PALI Health Care
- CPHI Health Care
- Exchange
- PALI Nasdaq
- CPHI Nasdaq
- Market Cap
- PALI 3.5M
- CPHI 4.2M
- IPO Year
- PALI N/A
- CPHI N/A
- Fundamental
- Price
- PALI $2.52
- CPHI $0.19
- Analyst Decision
- PALI Strong Buy
- CPHI
- Analyst Count
- PALI 1
- CPHI 0
- Target Price
- PALI $8.00
- CPHI N/A
- AVG Volume (30 Days)
- PALI 198.8K
- CPHI 385.4K
- Earning Date
- PALI 11-12-2024
- CPHI 11-13-2024
- Dividend Yield
- PALI N/A
- CPHI N/A
- EPS Growth
- PALI N/A
- CPHI N/A
- EPS
- PALI N/A
- CPHI N/A
- Revenue
- PALI N/A
- CPHI $5,544,620.00
- Revenue This Year
- PALI N/A
- CPHI N/A
- Revenue Next Year
- PALI N/A
- CPHI N/A
- P/E Ratio
- PALI N/A
- CPHI N/A
- Revenue Growth
- PALI N/A
- CPHI N/A
- 52 Week Low
- PALI $2.18
- CPHI $0.17
- 52 Week High
- PALI $22.35
- CPHI $1.15
- Technical
- Relative Strength Index (RSI)
- PALI 38.02
- CPHI 32.94
- Support Level
- PALI $2.20
- CPHI $0.18
- Resistance Level
- PALI $2.71
- CPHI $0.27
- Average True Range (ATR)
- PALI 0.31
- CPHI 0.02
- MACD
- PALI -0.03
- CPHI -0.01
- Stochastic Oscillator
- PALI 25.76
- CPHI 13.22
About PALI Palisade Bio Inc.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
About CPHI China Pharma Holdings Inc.
China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection and others.